Brief: Sunesis Pharmaceuticals Plans To Review Strategic Alternatives

Viracta Therapeutics

07/07/2020 21:13

July 7 (Reuters) - Sunesis Pharmaceuticals Inc  SNSS.O :
    * SUNESIS PHARMACEUTICALS PROVIDES CORPORATE UPDATE
    * SUNESIS PHARMACEUTICALS - REDUCTION IN WORKFORCE OF ABOUT
30% OF
HEAD COUNT TO FOCUS ON DEVELOPMENT OF ITS FIRST-IN-CLASS PDK1
INHIBITOR SNS-510
    * SUNESIS PHARMACEUTICALS INC SAYS REDUCTION IN WORKFORCE IS
TO
RIGHT SIZE COMPANY TO ACHIEVE ITS OBJECTIVES AND PRESERVE CASH
RESOURCES
    * SUNESIS PHARMACEUTICALS INC - REDUCTION IN WORKFORCE IS
EXPECTED
TO BE COMPLETED DURING CURRENT QUARTER
    * SUNESIS PHARMACEUTICALS INC SAYS WILL PROVIDE COMPANY
SUFFICIENT
CASH TO FUND ITS OPERATIONS INTO Q2 OF 2021
    * SUNESIS PHARMACEUTICALS INC - PLANS TO REVIEW STRATEGIC
ALTERNATIVES

Source text for Eikon:  ID:nGNX43MLdJ 
Further company coverage:  SNSS.O 

 (Reuters.Briefs@thomsonreuters.com)